Form 4: Pfizer Director James C. Smith Reports Acquisition of Phantom Stock Units

Director James C. Smith reported the acquisition of phantom stock units representing deferred director's compensation.

Summary

• On September 30, 2024, James C. Smith, a director of Pfizer Inc., acquired 1,554.941 phantom stock units.
• These units represent deferred director's compensation, including dividend equivalents.
• The units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
• The price of the phantom stock units was $28.94.
• Following the transaction, Smith beneficially owns 135,661.069 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices, indicating alignment of interests between the director and shareholders.

Future Outlook

The phantom stock units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.

Industry Context

This filing is a routine disclosure of a director's compensation in the form of phantom stock units, which is a common practice in corporate governance to align the interests of directors with those of shareholders.

Stakeholder Impact

• The acquisition of phantom stock units aligns the director's interests with those of the shareholders, potentially encouraging decisions that benefit the company's long-term performance.

Key Dates